Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Diovan Group (valsartan by Year
Diovan Group (valsartan — hypertension & heart failure) ($M)
Novartis Diovan Group (valsartan: $604M in FY2025, up 2.4% from a year earlier.
Latest, FY2025
604
Period ended Dec 31, 2025
Change on a year earlier
+2.4%
590 in FY2024
History
9 years
Since FY2017
Sources
7
Documents cited below
Where the FY2025 figure comes from
“|| Diovan Group | 604 | 590 | 2 | 2”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Diovan Group (valsartan — hypertension & heart failure) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 604 | +2.4% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 590 | -3.8% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 613 | -6.0% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 652 | -15.7% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | 773 | -22.9% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2020 | Dec 31, 2020 | 1,003 | -5.7% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2019 | Dec 31, 2019 | 1,064 | +4.0% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2018 | Dec 31, 2018 | 1,023 | +6.9% | Novartis Form 6-K (0001370368-20-000007) ↗ |
| FY2017 | Dec 31, 2017 | 957 | – | Novartis Form 6-K (0001370368-19-000006) ↗ |
Breakdown
What makes up diovan Group (valsartan
Cite this data
StockData. (2026). Novartis Diovan Group (valsartan ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-diovan-group
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.